KM-819 is under clinical development by Fascinate Therapeutics and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KM-819’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KM-819 is under development for the treatment of Parkinson’s disease and multiple system atrophy. The drug candidate is administered through oral route. The drug candidate acts by targeting fas-associated factor 1 (FAF1).
Fascinate Therapeutics overview
FAScinate Therapeutics, Inc., a healthcare company that develops novel drugs and therapeutics intended for the treatment of Parkinson’s disease. The company is headquartered in United States.
For a complete picture of KM-819’s drug-specific PTSR and LoA scores, buy the report here.